Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Pegylated liposomal doxorubicin + RO6839921 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pegylated liposomal doxorubicin | Doxil | ATI-0918|CAELYX|liposomal doxorubicin | Chemotherapy - Anthracycline 13 | Doxil (pegylated liposomal doxorubicin) comprises the anthracyline doxorubicin, which intercalates into DNA and disrupts DNA replication, encapsulated in a liposome, which improves tumor penetration and decreases toxicity (NCI Drug Dictionary), and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov). |
RO6839921 | RO-6839921 | MDM2 Inhibitor 23 | RO6839921 is a pegylated prodrug of idasanutlin that binds to MDM2 and inhibits its interaction with p53, preventing degradation of p53, thereby potentially resulting in restoration of wild-type p53 activity and apoptosis of tumor cells (PMID: 31734832, PMID: 32020437). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 wild-type | fibrosarcoma | sensitive | Pegylated liposomal doxorubicin + RO6839921 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, RO6839921 and Doxil combination treatment demonstrated sustained survival benefit in TP53 wild-type fibrosarcoma cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|